The VC Math Ain’t Mathin’: This Health Investor Has a Fresh Playbook
AI-summarised brief · reviewed before publication
Venture capital’s traditional model faces scrutiny in health tech despite a market recovery, with $7.4 billion raised in the first half of 2026. Funding is highly concentrated, as mega-rounds absorb nearly half the capital, creating a divided market. Liquidity remains challenging, marked by zero IPOs in H1 2026 and an exit backlog for mature companies. Allumia Ventures’ Dan Galles highlights healthcare’s inherent difficulties, including slow adoption and few new institutional customers. While private practices offer entry, they are financially constrained. Self-insured employers and consumer-facing platforms, such as Hinge Health and Hims & Hers, prove more viable for scaling. Although AI offers promise, it also benefits incumbents. Galles advocates a new VC playbook that pursues billion-dollar exits but also enables attractive $150 million to $250 million outcomes. This strategy focuses on early commercial adoption, efficient capital use, and profitability, aligning investment approaches with realistic exit potentials in a complex landscape.
💡 Why It Matters
- · The shift toward mid-sized exits challenges the industry's reliance on unicorn valuations, forcing investors to prioritize sustainable profitability over speculative growth.
- · This recalibration redefines success metrics for health tech startups in a liquidity-constrained environment.
